Please assess the completion status of the following clinical trial:

Trial Title: Addressing Dementia Via Agitation-Centered Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.~* Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.~Exclusion Criteria:~* Patient has dementia predominantly of non-Alzheimer's type.~* Unable to comply with study procedures.~* Medically inappropriate for study participation in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- AXS-05 (Type: EXPERIMENTAL): AXS-05 tablets taken by mouth for 5 weeks.
- Bupropion (Type: ACTIVE_COMPARATOR): Bupropion tablets taken by mouth for 5 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets taken by mouth for 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).